FoxBioNet Pilot Project: SAVE (Synuclein Assay Validation Effort)

Inclusion Criteria: Parkinson's Disease Subjects * Patients must meet the MDS criteria for Parkinson's disease. * Disease duration: any * Male or female age 30 years or older at time of PD diagnosis. Control Subjects * Male or female age 30 years or older at Screening. Exclusion Criteria: Parkinson's Disease Subjects * Inability to provide informed consent * Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude safe completion of the lumbar puncture. * Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia. * Participation in a blinded clinical trial of any kind or an unblinded trial of an investigational product that is not currently approved for use in humans. Control Subjects * Inability to provide informed consent * Current treatment with anticoagulants (e.g. coumadin, heparin) that might preclude safe completion of the lumbar puncture. * Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia. * Participation in a blinded clinical trial of any kind or an unblinded trial of an investigational product that is not currently approved for use in humans. * The presence of rest tremor, bradykinesia or rigidity. * The presence of any other neurological sign that in the opinion of the site investigator raises suspicion for an atypical parkinsonian syndrome (e.g. supranuclear gaze palsy)